Equities analysts forecast that Paragon 28 will post -0.64 earnings per share for the current fiscal year. Paragon 28, Inc develops, distributes, and sells foot and ankle surgical systems in the ...
Analysts expect that Paragon 28, Inc. will post -0.64 EPS for the current year. Paragon 28, Inc develops, distributes, and sells foot and ankle surgical systems in the United States and ...
Hosted on MSN1mon
Strength Seen in Paragon 28, Inc. (FNA): Can Its 8.3% Jump Turn into More Strength?Zimmer Biomet agreed to buy Paragon 28 for an equity value of approximately $1.1 billion. The deal is expected to close in the first half of 2025. This company is expected to post quarterly loss ...
NEW YORK, NY / ACCESS Newswire / March 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers ...
Paragon 2 (FNA) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976in connection with the previously announced acquisition of Paragon 28 ...
ENGLEWOOD, Colo., March 07, 2025--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, is pleased to ...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Paragon 28, Inc. (NYSE: FNA) to Zimmer Biomet Holdings, Inc. for $13.00 per share in ...
ENGLEWOOD, Colo., March 11, 2025--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA) ("Paragon 28" or "Company"), a leading medical device company exclusively focused on the foot and ankle orthopedic ...
Paragon 28, Inc. (NYSE: FNA) (“Paragon 28” or “Company”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the expiration of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback